FGF-5 Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $47.00 $143.00 $680.00 | 16 | |
PD173074 is a small molecule inhibitor that directly targets FGF receptor tyrosine kinases. Specifically, it inhibits the tyrosine kinase activity of FGFR1, FGFR2, and FGFR3. By binding to the ATP-binding pocket of these receptors, PD173074 disrupts the autophosphorylation process, preventing downstream signaling cascades initiated by FGF-5 binding. | ||||||
BGJ398 | 872511-34-7 | sc-364430 sc-364430A sc-364430B sc-364430C | 5 mg 10 mg 50 mg 100 mg | $216.00 $252.00 $594.00 $1009.00 | 4 | |
BGJ398 is a selective FGFR inhibitor that directly targets FGFR1, FGFR2, and FGFR3. By binding to the ATP-binding site of these receptors, it inhibits their tyrosine kinase activity, blocking downstream signaling events initiated by FGF-5. | ||||||
AZD4547 | 1035270-39-3 | sc-364421 sc-364421A | 5 mg 10 mg | $198.00 $309.00 | 6 | |
AZD4547 is a bioavailable FGFR tyrosine kinase inhibitor with selectivity for FGFR1, FGFR2, and FGFR3. It directly interferes with the ATP-binding site of these receptors, inhibiting their autophosphorylation and subsequent downstream signaling triggered by FGF-5 binding. This disruption in signaling pathways results in the modulation of cellular responses associated with FGF-5, particularly affecting processes related to cell growth and differentiation. | ||||||
Debio-1347 | 1265229-25-1 | sc-507386 | 10 mg | $324.00 | ||
Debio 1347 is a selective FGFR tyrosine kinase inhibitor with specificity for FGFR1, FGFR2, FGFR3, and FGFR4. It directly interferes with the ATP-binding site of these receptors, inhibiting their autophosphorylation and subsequent downstream signaling initiated by FGF-5. This interference leads to the modulation of cellular responses associated with FGF-5, particularly impacting cell proliferation and differentiation processes. | ||||||
Dovitinib, Free Base | 405169-16-6 | sc-396771 sc-396771A | 10 mg 25 mg | $170.00 $350.00 | ||
Dovitinib is a multitargeted receptor tyrosine kinase inhibitor that inhibits FGFR1, FGFR2, FGFR3, and FGFR4. By blocking the ATP-binding site of these receptors, Dovitinib prevents their autophosphorylation and downstream signaling cascades initiated by FGF-5 binding. This interference leads to the modulation of cellular responses associated with FGF-5, particularly affecting processes related to cell proliferation and differentiation. | ||||||
Erdafitinib | 1346242-81-6 | sc-507388 | 10 mg | $138.00 | ||
Erdafitinib is a pan-FGFR inhibitor that directly targets FGFR1, FGFR2, FGFR3, and FGFR4. By binding to the ATP-binding site of these receptors, it inhibits their tyrosine kinase activity, preventing the autophosphorylation crucial for downstream signaling initiated by FGF-5. This interference leads to the modulation of cellular responses associated with FGF-5, particularly affecting processes related to cell growth and differentiation. | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $175.00 $983.00 | 2 | |
AP 24534 (Ponatinib) is a multi-tyrosine kinase inhibitor that inhibits FGFR1, FGFR2, FGFR3, and FGFR4. By targeting the ATP-binding site of these receptors, Ponatinib blocks their autophosphorylation and downstream signaling cascades initiated by FGF-5 binding. This interference leads to the modulation of cellular responses associated with FGF-5, particularly affecting processes related to cell proliferation and differentiation. | ||||||